Domestic Value Addition: KSM Reconciliation for PLI Category 2

A Category 2 Active Pharmaceutical Ingredient applicant on the Department of Pharmaceuticals PLI Pharma Rs 15,000 crore scheme — the persona anchored in the Hyderabad-Bollaram-Bachupally API belt where a Tier 2 API-and-KSM major of the scale of Neuland Laboratories or Suven Pharmaceuticals operates a chemical-synthesis Chapter 29 API portfolio — closes its Q4 FY 2026-27 quarterly claim on the DoP PLI portal for a single eligible product (illustratively a Ch 29 nootropic API such as Levetiracetam). Ex-factory value for the year sits at approximately Rs 82 crore. Imported inputs total Rs 26 crore across Chinese Diethyl malonate KSM at Rs 12 crore, Chinese 2-Chloropyridine intermediate at Rs 8 crore, and a stack of imported solvents at Rs 6 crore. Domestic inputs — Indian KSMs sourced from Divi’s Laboratories and other domestic Ch 29 suppliers, local intermediates, Indian plant labour, and utility overheads — aggregate to Rs 56 crore. Domestic Value Addition on the (ex-factory minus imported inputs) over ex-factory formula lands at 68.3 percent — safely above the 50 percent minimum Category 2 KSM threshold. This is PLI Pharma domestic value addition KSM Category 2 reconciliation at operating scale for a mid-sized API applicant, and the discipline that keeps the DVA trend clear of the 50 percent floor across every quarter of the six-year scheme window is what separates an applicant whose Ind AS 20 grant recognition runs on schedule from one whose Q3-shock quarter fails the DVA test and forfeits the quarter’s incentive.

Quick reference

The reconciliation in one paragraph

A Category 2 API applicant runs a four-surface reconciliation cascade every quarter. Surface one is the BOM-level composition register for each eligible product — every input line tagged with country-of-origin (domestic or imported), HSN chapter, vendor master reference, and invoice-level unit rate, anchored to the ERP material master. Surface two is the monthly ex-factory value extract from the ERP sales ledger, keyed on the eligible-product material code and cross-referenced against the applicable base-year and incremental-sales computation carried forward from the Wave A PLI Pharma Rs 15,000 crore eligibility and incremental sales cornerstone. Surface three is the DVA computation per eligible product — (ex-factory minus imported inputs) divided by ex-factory — tracked at monthly cadence with amber-zone and red-zone bands, aggregated to the quarterly DVA disclosed on the DoP PLI portal claim workbook. Surface four is the intra-group KSM transfer overlay — the domestic KSM manufactured by a sister-company subsidiary that enters the DVA numerator through the domestic-input leg, priced under Section 92BA specified-domestic-transaction Rule 10D transfer-pricing documentation. Each surface is a distinct reconciliation and each carries its own DoP portal, statutory auditor, and Section 92BA scrutiny exposure.

What the scenario looks like in India — the illustrative Category 2 persona

The Category 2 API-and-KSM applicant universe on the PLI Pharma Rs 15,000 crore scheme sits inside a well-defined domestic manufacturing geography. The Telangana-Andhra Pradesh belt — Hyderabad, Bollaram, Bachupally, Vishakhapatnam, Kakinada — hosts the largest concentration of chemical-synthesis Ch 29 API and KSM capacity, with Divi’s Laboratories (Bollaram, Vishakhapatnam, Kakinada), Aurobindo Pharma’s API subsidiary Aurobindo Pharma Ltd (Hyderabad campus), Neuland Laboratories (Bonthapally and Pashamylaram), Suven Pharmaceuticals (Suryapet and Pashamylaram), and Laurus Labs (Vishakhapatnam) anchoring the belt. Gujarat’s Ankleshwar, Vadodara and Halol corridors carry the balance of API-focused Ch 29 capacity for both integrated pharma majors (Sun Pharmaceutical Industries, Zydus Lifesciences, Torrent Pharmaceuticals) and specialist API makers. The Maharashtra-Karnataka belt hosts Piramal Pharma’s Digwal API site (technically Telangana but Piramal-managed), Ipca Laboratories’ Ratlam and Aurangabad plants, and Biocon’s Bengaluru fermentation campuses on the fermentation-based Category 2 leg.

For the illustrative worked example in this article, we take a Category 2 API applicant at the scale of a Tier 2 Ch 29 API-and-KSM major operating a chemical-synthesis Levetiracetam line — the Neuland Labs profile for a single-eligible-product Category 2 filing under the PLI Pharma scheme. The persona is illustrative; real PLI Pharma applicant lists, per-product DVA disclosures, and DoP-approved eligible products are disclosed in aggregate by the Department of Pharmaceuticals and are not the subject of speculative recomputation here. The reconciliation surface — how a Category 2 API applicant runs the DVA workbook — is the substance of the article, not the identity of any specific real applicant.

The regulatory overlay — DVA formula, Category 2 threshold, KSM-in-KSM double-integration, Section 92BA

Four regulatory anchors govern the Category 2 DVA reconciliation, and each maps to a distinct control surface on the quarterly claim workbook.

The PLI Pharma scheme guidelines notified by the Department of Pharmaceuticals set the Category 2 minimum DVA threshold at 50 percent for KSM applications. The formula is DVA equals Ex-factory Value of the eligible product minus Value of Imported Inputs, divided by Ex-factory Value, expressed as a percentage. Ex-factory Value is the price at which the eligible product is sold at the plant gate — GST-exclusive, excise-legacy-exclusive, and freight-exclusive. Value of Imported Inputs is the aggregate landed cost of every imported input consumed in the manufacture of the eligible-product output in the same period — Chinese or European or Japanese KSMs, imported intermediates, imported solvents, imported catalysts, imported specialty reagents. The formula is tested at the individual eligible-product level, not on an aggregate applicant portfolio basis. A quarter in which one product’s DVA drops below 50 percent renders that product’s sales ineligible for the quarter, while other eligible products in the same applicant portfolio that still clear the threshold continue to accrue claim.

The Category 2 incentive rate schedule stacks against the DVA-passed eligible-product incremental sales. Category 2 rates are 10 percent of eligible incremental sales for Years 1 and 2, 8 percent for Years 3 and 4, and 6 percent for Years 5 and 6. Incremental sales are computed against the FY 2019-20 base sales value approved by the Project Management Agency at scheme entry — the base-year discipline is the same as for Category 1 and is walked through in detail in the Wave A cornerstone. The Category 2 per-applicant per-year cap sits separately in the scheme guidelines. The DVA test is a pass-or-fail gate that precedes the incentive computation — a failed quarter contributes zero incentive regardless of the incremental sales volume.

The KSM-in-KSM double-integration story is the strategic hedge that a Category 2 applicant builds against the recurring China-supply-crunch risk. If the applicant not only manufactures the finished Ch 29 API in India but also backward-integrates the KSM for that API domestically — either at the same plant or at a sister-company subsidiary — the imported KSM value drops out of the DVA numerator’s negative leg and the domestic KSM value adds to the DVA numerator’s positive leg. Continuing the illustrative persona, if the applicant were to bring Diethyl malonate manufacture in-house in India, displacing the Rs 12 crore Chinese import, the imported-input value drops from Rs 26 crore to Rs 14 crore and DVA rises from 68.3 percent to 82.9 percent — a hedge of roughly 15 DVA percentage points against a supply-crunch scenario. The backward-integration mechanic and its transfer-pricing implications are elaborated in the Wave B backward-integration API manufacturing transfer pricing pharma guide and cross-refer to the API vs formulation HSN 2941/3003/3004 reconciliation guide.

Section 92BA of the Income-tax Act 1961 read with Rule 10D governs the transfer-pricing documentation for the intra-group KSM transfer where the domestic KSM is manufactured by a sister-company subsidiary within the same corporate group. The transfer price must be at arm’s length against a comparable-uncontrolled-price, cost-plus, or transactional-net-margin benchmark. The reconciliation surface is that the transfer price used in the DVA composition register must match the transfer price documented under Rule 10D. A single intra-group KSM transfer register — feeding both the DVA workbook (domestic-input value line) and the Rule 10D transfer-pricing file (arm’s-length benchmark) — is the discipline that keeps the two regimes in sync.

A worked example — an illustrative Category 2 Ch 29 API applicant at Q4 close

Illustrative — the following figures represent the operating pattern of a Category 2 Ch 29 API applicant on the PLI Pharma scheme at the scale of a Tier 2 API-and-KSM major running a chemical-synthesis nootropic API line. Public disclosures do not reveal per-eligible-product per-quarter DVA composition breakdowns; the numbers below are illustrative of the reconciliation surface, not a claim about any specific real applicant’s PLI position.

The illustrative persona is a Category 2 Ch 29 API applicant filing on a single eligible product — Levetiracetam — for FY 2026-27. The applicant’s Q4 FY 2026-27 claim workbook on the DoP PLI portal shows the following DVA composition build:

The 68.3 percent DVA is 18.3 percentage points above the 50 percent threshold — comfortably clear of the amber zone (55 percent) and the red zone (52 percent) alert bands the applicant maintains on its monthly DVA trend monitor. The eligible-product sales of Rs 82 crore feed the Category 2 incentive computation for the year against the FY 2019-20 base at the Year-appropriate rate.

Now consider a China-supply-crunch scenario in the same year. Chinese Diethyl malonate landed cost rises 40 percent — from Rs 12 crore to Rs 17 crore — driven by a mid-year anti-dumping duty change or an environmental clearance shutdown at a Chinese source plant. Chinese 2-Chloropyridine similarly moves from Rs 8 crore to Rs 11 crore. Imported solvents rise from Rs 6 crore to Rs 7.5 crore on freight inflation and INR-USD movement. Aggregate imported inputs move to Rs 35.5 crore. Ex-factory value moves to Rs 84 crore (a modest pass-through of the input cost). DVA drops to (84 minus 35.5) / 84 = 57.7 percent — still above the 50 percent floor but now inside the amber zone (below 60 percent), triggering the monthly review with finance and plant leadership.

A more severe shock scenario: aggregate imported inputs move to Rs 42 crore against ex-factory Rs 84 crore. DVA drops to 50.0 percent — sitting exactly on the floor. Any further deterioration pushes the eligible-product Q4 filing into a failed-DVA quarter, and the Q4 incentive claim on the affected product forfeits. The Ind AS 20 grant receivable for Q4 on that product is not accrued (or is reversed if the earlier accrual was based on a passing Q3 trend). The KSM-in-KSM double-integration hedge — bringing Diethyl malonate manufacture in-house domestically — is what protects the DVA against exactly this scenario, and the strategic case for the domestic KSM plant is often built directly on the DVA-floor risk analysis rather than on unit-economics alone.

Common reconciliation breakages

Four breakages recur across Category 2 DVA claim runs, and each maps to a specific control failure.

• BOM-level country-of-origin flag missing or stale on the vendor master. The applicant’s SAP MM vendor master or Oracle Fusion supplier master carries a country-of-origin field, but that field is often set at vendor onboarding and never refreshed. A domestic vendor that pivots to importing its own raw material (a Divi’s Labs-type domestic KSM supplier that itself imports the KSM’s KSM from China) still shows domestic in the vendor master, and the imported content passes through into the DVA numerator as domestic — inflating the DVA percentage optically while the DoP scrutiny team can pull the vendor’s own import register. The reconciliation surface is a periodic vendor-master country-of-origin refresh, tied to the DGFT importer-exporter-code database cross-check for material vendors, and a flag on any vendor whose import percentage of its own inputs crosses a threshold. The failure mode is documented in Terra Insight’s reconciliation failure-mode analysis for India methodology.

• Intra-group KSM transfer price divergence between DVA workbook and Section 92BA file. The applicant with a sister-company KSM subsidiary uses one transfer price in the DVA workbook (domestic-input value) and a different arm’s-length benchmark price in the Rule 10D transfer-pricing file — either because the two workstreams sit in different corporate functions (finance versus tax) or because the DVA workbook was built earlier at cost-plus and the transfer-pricing file was refreshed later at the transactional-net-margin benchmark. A DoP scrutiny cycle or a Section 92BA transfer-pricing officer that cross-references the two documents surfaces the divergence and can either disallow the DVA composition or impute a transfer-pricing adjustment. The reconciliation discipline is a single intra-group KSM transfer register that feeds both regimes consistently.

• Ex-factory value inclusion or exclusion of GST, excise-legacy duty, or plant-gate freight. The DVA formula uses ex-factory value as the denominator. Applicants that key the ex-factory value off the GST-inclusive invoice line — rather than the GST-exclusive assessable value — inflate the denominator, inflate the DVA percentage, and mis-state the composition. Applicants that key off a freight-inclusive plant-gate value where the freight is a domestic-service cost that should be separately treated in the DVA computation also mis-state. The reconciliation discipline is an ex-factory value extract from the ERP sales ledger keyed on the assessable-value line, GST-exclusive, freight-exclusive, and rebate-exclusive.

• Monthly DVA trend monitor absent — first surprise at quarter-end. Applicants that only compute DVA at quarter-end for the claim workbook filing lose the ability to intervene in a supply-crunch quarter before the quarter closes. A monthly DVA trend at eligible-product level, with the amber-zone (55 percent) and red-zone (52 percent) alert bands, gives the procurement team, the plant leadership, and the finance team six to twelve weeks of runway to substitute a domestic supplier for a Chinese source, accelerate a KSM-in-KSM backward-integration commissioning, or adjust the eligible-product mix within the portfolio. The monthly cadence is the specific control test in Terra Insight’s reconciliation playbook monthly close framework applied to PLI Category 2 governance.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the BOM-level composition register with per-input country-of-origin classification, the ERP sales ledger extract for ex-factory value by eligible product, the ERP procurement ledger extract for imported-input value tracked at BOM-line granularity, the intra-group KSM transfer register with the Section 92BA Rule 10D transfer-pricing reference, and the vendor-master country-of-origin refresh — and produces a monthly DVA trend per eligible product with the 50 percent threshold overlay, amber-zone and red-zone alert bands, and a quarterly DoP PLI portal claim workbook draft that discloses the DVA composition, the imported-input country-of-origin breakdown, and the intra-group KSM transfer disclosure line. Match rate improvement of 51 to 88 percent on the ex-factory value and imported-input reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Category 2 API-and-KSM applicant running a multi-product PLI Pharma claim stack — enabling the finance team to keep the DVA on the right side of the 50 percent floor across every quarter of the six-year scheme window without a spreadsheet crisis at every close. The commercial pillar for the sub-cluster is pharma reconciliation software India.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 16 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024